Traded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Apr 1, 2026 · Filed Apr 2, 2026
A ResMed| director sold $450K of ResMed| shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$450,000
Shares × reported transaction price
62 days after results of Jan 29, 2026, 29 days before results of Apr 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $222.85 on Apr 1, 2026, 9% above its 52-week low and 24% below its high, after a 14% drop over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 21% of the way up, from 251 adjusted closes. 30 trading days earlier: $258.91 on Feb 18, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +2.4% | +4.1% | −1.8% |
| 30 days | −6.8% | +11.4% | −18.2% |
| 90 days | −2.9% | +14.0% | −16.9% |
| 180 days | −0.9% | +17.6% | −18.5% |
Past results only. Not a forecast.
Traded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Michael J. Farrell (Chairman and CEO) sold ~$1.13M of ResMed|
Scheduled in advanceTraded Apr 7 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.